Bicara Therapeutics Inc (BCAX) PT Lowered to $44 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns lowered the price target on Bicara Therapeutics Inc (NASDAQ: BCAX) to $44.00 (from $45.00) while maintaining a Buy rating.

The analyst commented: "Looking ahead, we point out the following catalysts to investors, including: (1) presentation of three datasets at AACR later this month (i.e., dose expansion results for ficerafusp alfa in 2L+ cSCC patients [Abstract #CT034], analysis of paired biopsies results from the Phase 1b HPV- 1L R/M head and neck squamous cell carcinoma (HNSCC) cohort that highlight the potential of ficerafusp alfa to overcome resistance mechanisms in combination with Keytruda (pembrolizumab) [Abstract #3284], and preclinical data that shows that ficerafusp alfa reverses acquired resistance to LUMAKRAS (sotorasib) in KRASG12C+ lung tumors [Abstract #4434]); (2) updated clinical results from the ongoing Phase 1/1b study of ficerafusp alfa + Keytruda in 1L R/M HNSCC at ASCO 2025; and (3) initiation of a Phase 1b expansion cohort evaluating ficerafusp alfa +/- Keytruda in patients with 3L+ RAS-/BRAF-wild type mCRC in 2025. After factoring in higher operating expenses moving forward, we reiterate our Buy rating, while modulating our 12-month price target to $44 from the prior $45 per share."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Phillips 66, Marathon Merger Talks Collapsed - Semafor
• Aurora Spine settles patent dispute, secures $600K insider loan